LLY

988.33

+0.72%↑

JNJ

240.32

+0.33%↑

ABBV

229.95

-0.9%↓

NVS

159.76

-0.49%↓

AZN

194.37

-1.51%↓

LLY

988.33

+0.72%↑

JNJ

240.32

+0.33%↑

ABBV

229.95

-0.9%↓

NVS

159.76

-0.49%↓

AZN

194.37

-1.51%↓

LLY

988.33

+0.72%↑

JNJ

240.32

+0.33%↑

ABBV

229.95

-0.9%↓

NVS

159.76

-0.49%↓

AZN

194.37

-1.51%↓

LLY

988.33

+0.72%↑

JNJ

240.32

+0.33%↑

ABBV

229.95

-0.9%↓

NVS

159.76

-0.49%↓

AZN

194.37

-1.51%↓

LLY

988.33

+0.72%↑

JNJ

240.32

+0.33%↑

ABBV

229.95

-0.9%↓

NVS

159.76

-0.49%↓

AZN

194.37

-1.51%↓

Начало・Списък с акции・Editas Medicine Inc

Editas Medicine Inc

Затворен

СекторЗдравеопазване

2 5.82

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

1.96

Максимум

2.03

Ключови измерители
By Trading Economics
Приходи	28M -25M
Продажби	4M 7.5M
Марж на печалбата	-332.984
Служители	246
EBITDA	27M -22M

Препоръки
By TipRanks
Препоръки	Продай
12-месечна прогноза	+100% upside

Дивиденти
By Dow Jones
Следващи печалби	11.03.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-65M 210M
Предишно отваряне	-3.82
Предишно затваряне	2

Настроения в новините

By Acuity

50%

128 / 351 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Very Strong Bearish Evidence

1.33 / 1.54 Подкрепа & съпротива

Editas Medicine Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

6.03.2026 г., 19:32 ч. UTC

Придобивния, сливания и поглъщания

Diana Shipping Increases Offer to Acquire Genco -- Update

8.03.2026 г., 23:47 ч. UTC

Пазарно говорене

Значими събития в новините

Global Equities Roundup: Market Talk

8.03.2026 г., 23:47 ч. UTC

Пазарно говорене

Значими събития в новините

Nikkei May Fall on Higher Energy Prices, Signs of U.S. Econ Weakness -- Market Talk

8.03.2026 г., 23:46 ч. UTC

Пазарно говорене

Значими събития в новините

Gold Falls Amid Dollar's Strength -- Market Talk

8.03.2026 г., 23:34 ч. UTC

Пазарно говорене

Значими събития в новините

Oil Futures Surge Above $100/bbl Amid Growing Middle East Conflict -- Market Talk

8.03.2026 г., 23:08 ч. UTC

Значими събития в новините

Front-month WTI Crude Futures Jump 16.6%, Front-Month Brent Crude Futures Climb 15.2%

8.03.2026 г., 23:05 ч. UTC

Значими събития в новините

Front-month Crude Oil Futures Surge Amid Rising Middle East Conflict

8.03.2026 г., 22:37 ч. UTC

Значими събития в новините

The Long-Feared Persian Gulf Oil Squeeze Is Upon -2-

8.03.2026 г., 22:37 ч. UTC

Значими събития в новините

The Long-Feared Persian Gulf Oil Squeeze Is Upon Us -- WSJ

7.03.2026 г., 02:30 ч. UTC

Значими събития в новините

Iran War Is Kicking India When It's Already Down -- Barrons.com

6.03.2026 г., 22:26 ч. UTC

Значими събития в новините

Why $100 Oil Is Now in Sight. Who Wins, Who Loses. -- Barrons.com

6.03.2026 г., 22:07 ч. UTC

Пазарно говорене

Придобивния, сливания и поглъщания

Boeing Says Spirit Acquisition Will Help Improve Safety -- Market Talk

6.03.2026 г., 22:03 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

6.03.2026 г., 22:03 ч. UTC

Пазарно говорене

Boeing CEO's Pay Nears $24 Million During Recovery Phase -- Market Talk

6.03.2026 г., 21:50 ч. UTC

Пазарно говорене

Значими събития в новините

Financial Services Roundup: Market Talk

6.03.2026 г., 21:37 ч. UTC

Печалби

Salesforce Stock Might Not Be an AI Loser After All -- Barrons.com

6.03.2026 г., 21:25 ч. UTC

Значими събития в новините

How The Iran War Impacts Ukraine. -- Barrons.com

6.03.2026 г., 21:17 ч. UTC

Печалби

Burlington Stores' Strong Year Should Lift the Stock. What Comes Next. -- Barrons.com

6.03.2026 г., 20:50 ч. UTC

Печалби

Marvell Stock Pops 20%. Semiconductor Earnings Show AI Demand Is Strong. -- Barrons.com

6.03.2026 г., 20:46 ч. UTC

Печалби

Nike Reports $300 Million Pretax Charge Related to Job Cuts -- Barrons.com

6.03.2026 г., 20:31 ч. UTC

Значими събития в новините

Oil Prices Soar Past $90. Trump Demands 'Unconditional Surrender' From Iran -- and Kuwait Cut Production. -- Barrons.com

6.03.2026 г., 20:18 ч. UTC

Пазарно говорене

Oil Makes Record Weekly Gains As Strait of Hormuz Stays Shut -- Market Talk

6.03.2026 г., 20:12 ч. UTC

Пазарно говорене

Значими събития в новините

U.S. Natural Gas Futures Gain on Global Energy Turmoil -- Market Talk

6.03.2026 г., 19:10 ч. UTC

Пазарно говорене

Значими събития в новините

$150 Oil Seen As Realistic If Hormuz Closure Lasts -- Market Talk

6.03.2026 г., 18:54 ч. UTC

Пазарно говорене

Fed's Hammack: Dollar Hasn't Lost Prime Status -- Market Talk

6.03.2026 г., 18:44 ч. UTC

Пазарно говорене

Значими събития в новините

U.S. Oil Rig Count Increases By 4 to 411 -- Market Talk

6.03.2026 г., 18:08 ч. UTC

Печалби

Samsara Stock Jumps 16% After Earnings. Why the CEO Isn't Worried About AI. -- Barrons.com

6.03.2026 г., 18:04 ч. UTC

Печалби

Marvell Stock Surges on Earnings. It's Not Just a Custom AI Chip Story. -- Barrons.com

6.03.2026 г., 18:04 ч. UTC

Печалби

Samsara Stock Jumps 16% After Earnings. Why the CEO Isn't Worried About AI. -- Barrons.com

6.03.2026 г., 17:49 ч. UTC

Пазарно говорене

AI-Driven Picks-And-Shovels Bet Comes With Risks -- Market Talk

Сравнение с други в отрасъла

Ценова промяна

Editas Medicine Inc Прогноза

Ценова цел

By TipRanks

100% нагоре

12-месечна прогноза

Среден 4 USD 100%

Висок 4 USD

Нисък 4 USD

Според 2 анализатори от Wall Street, предложили 12-месечна ценова цел за Editas Medicine Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Продай

2 ratings

Купи

Задържане

Продай

Според 2 анализатори, дали борсови рейтинги на Editas Medicine Inc през последните 3 месеца.

Техническа оценка

By Trading Central

1.33 / 1.54Подкрепа & съпротива

Recent bearish events outweigh bullish events.

The bullish and bearish events are balanced.

There are no events.

Настроение

By Acuity

128 / 351 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Editas Medicine Inc

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing alpha-beta T cells for solid and liquid tumors; and gamma delta T cell therapies to treat cancer. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; collaboration and nonexclusive license agreement with Genevant Sciences to develop Novel mRNA-LNP gene editing therapeuticsand strategic alliance and option agreement with Allergan Pharmaceuticals International Limited, as well as collaboration with Bristol Myers Squibb for research and development of alpha-beta T cell medicines for the treatment of cancer and autoimmune diseases. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.